

Meeting Abstract: 2014 ASCO Annual Meeting I

FREE ACCESS Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics May 20, 2014



Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients' avatars.

Authors: [Alberto Bardelli](#), [Sandra Misale](#), [Sabrina Arena](#), [Giulia Siravegna](#), [Simona Lamba](#), [Katia Bencardino](#), [Alessio Amatu](#), [Emanuele Valtorta](#), [Calogero Lauricella](#), [Andrea Sartore-Bianchi](#), [Federica Di Nicolantonio](#), and [Salvatore Siena](#) | [AUTHORS INFO & AFFILIATIONS](#)

Publication: Journal of Clinical Oncology Volume 32, Number 15 suppl https://doi.org/10.1200/jco.2014.32.15_suppl.2626



Abstract

2626

Background: The anti-EGFR antibodies cetuximab and panitumumab are approved for the treatment of RAS wild-type colorectal cancer (CRC) patients. The clinical efficacy of EGFR targeted antibodies is limited by the development of acquired (secondary) resistance. Here we investigated the molecular bases of relapse to anti-EGFR blockade in CRC cells and patients' samples and use xenotransplants to define a clinically applicable strategy to overcome acquired resistance. **Methods:** Molecular profiling of circulating tumor DNA was used to identify the emergence of mutations in plasma samples of patients who relapsed after anti EGFR therapies. Xenografted tumors (avatars) from patients who relapsed after EGFR blockade were established and exploited to assess the efficacy of drugs aimed at bypassing acquired resistance. **Results:** Emergence of concomitant mutations in KRAS and NRAS was detected in samples from 5 CRC patients who developed resistance to anti-EGFR antibodies. Acquired resistance to cetuximab and panitumumab was modeled in 4 CRC cell models. Resistant cells were a mixture of clones bearing alterations in KRAS, NRAS and BRAF thus closely recapitulating the patients' findings. Pathway analyses revealed that, although genetically polyclonal, resistant cells consistently displayed MEK and ERK activation but, surprisingly, were refractory to MEK inhibition. However, the resistant derivatives were sensitive to the concomitant inhibition of MEK and EGFR independently from their genetic status. Mouse xeno-transplants of lung and liver biopsies from two CRC patients who responded and subsequently relapsed upon EGFR therapy showed exquisite sensitivity to combinatorial treatment with the MEK inhibitor pimasertib and EGFR blockade with cetuximab. **Conclusions:** These observations provide a rational strategy to overcome the clonal heterogeneity that emerges when CRCs are treated with anti EGFR antibodies. We propose that MEK inhibitors, in combination with cetuximab or panitumumab, should be evaluated in CRC patients who become refractory to anti-EGFR therapies. A clinical trial (ARES) has been initiated to test this hypothesis.

This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text component.

ASCO® Career Center

Medical Hematologist/Oncologist - LLU/RUHS

Loma Linda, California | \$250,000 – \$330,000

Loma Linda University Faculty Medical Group (LLUFMG), Division of Medical Hematology/Oncology, is seeking Hematologists/Oncologists to join our exp...



Employer: Loma Linda University Faculty Medical Group [Apply for this job](#)

Medical Oncologist/Hematologist Opportunity in the San Francisco East Bay Area!

Walnut Creek, California (US) is a beautiful community in the East Bay Area. | Highly competitive salary with recruitment incentive opportunities

You will be practicing in our new state-of-the-art cancer treatment center in partnership with UCSF. Our world class facility brings...



Employer: John Muir Health Cancer Medical Group [Apply for this job](#)

Medical Oncologists/Hematologists - Metro Atlanta Area

Griffin, Georgia | Attractive Based, Bonus, and Benefits

NGOC is a growing practice of 29 physicians and 29 advance practice providers covering 13 office locations.



Recommended Articles

DEVELOPMENTAL THERAPEUTICS AND TRANSLATIONAL RESEARCH | MAY 01 2015

Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy...



Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy.

HEAD AND NECK CANCER | MAY 20, 2018

Mechanism of acquired resistance to cetuximab in head and neck cancer.

DEVELOPMENTAL THERAPEUTICS—CLINICAL PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | MAY 20, 2015

Sym004 to circumvent resistance to cetuximab driven by emergence of EGFR extracellular mutations in colorectal cancer.

TUMOR BIOLOGY | MAY 20, 2013

Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer.

JOURNALS

Journal of Clinical Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer Informatics
JCO Precision Oncology
JCO Oncology Advances

PUBLICATIONS

ASCO Educational Book
ASCO Daily News
ASCO Connection
The ASCO Post
ASCO Podcasts

CONTENT

Journal Podcasts
Topics
Meeting Abstracts
ASCO Guidelines

INFORMATION

Author Center
Subscriber Center
Permissions
Reprints
Advertise
E-Alerts
View My Profile
About ASCO Journals

FOLLOW US

JCO_ASCO
JCOOP_ASCO
JCOGO_ASCO
JCOPO_ASCO
JCOCCI_ASCO

ASCO

About ASCO
Press Center
Meetings & Education
Contact Us

ASCO WEBSITES

asco.org
ASCO Career Center
Conquer Cancer